An interventional study of Daily Walnut Consumption in CKD - Chronic Kidney Disease, Renal Function and Cardiovascular Biomarkers, sponsored by Institut Investigacio Sanitaria Pere Virgili. Recruiting at 1 site in Spain. Open to participants aged 45 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by Institut Investigacio Sanitaria Pere Virgili · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 188 studies in Renal Insufficiency, Chronic with a site in Spain — 38 open to participants now, 55 under way, 23 of them phase 3. Renal Insufficiency, Chronic · Spain.
Among the 188 studies in Renal Insufficiency, Chronic with a site in Spain, this one is the 94th largest by planned enrollment of the 154 interventional ones that give a count, is one of 15 that started in 2026, is one of 28 with no phase, reaches primary completion later than 32 of the 54 other live ones, and was the 186th registered.
3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.
Browse Renal Insufficiency, Chronic studies →38 of the 188 studies in Renal Insufficiency, Chronic with a site in Spain are open now. Recruiting first, the newest first:
Cardenal Herrera University · Sites in Spain
Ages 18–85
AstraZeneca · Sites in Spain, United States, Argentina and 24 more countries
Ages 18–99
AstraZeneca · Sites in Spain, United States, Argentina and 34 more countries
Ages 18+
Novartis Pharmaceuticals · Sites in Spain, United States, China and 5 more countries
Ages 2–18
Vifor Fresenius Medical Care Renal Pharma · Sites in Spain, China, Greece and 4 more countries
Ages 12–18
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.
This study: 45 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
188 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 34 · Phase 3 80 · Phase 4 14
First in 1998; this study’s year is marked. 15 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is above the median of 73 across 2,164 interventional studies indexed under Renal Insufficiency, Chronic.
Median enrollment 252 across the 154 interventional studies, 397 across the 34 observational. Of the 122 that completed or were terminated, 68 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
124 of 188 have an industry lead sponsor. The 10 most frequent:
Institut Investigacio Sanitaria Pere Virgili is the lead sponsor of 39 studies on the registry; 17 are open to participants now.
Institut Investigacio Sanitaria Pere Virgili has 1 study filed under Renal Insufficiency, Chronic — fewer than ten, so there is no comparison to draw.
13 of the studies in Renal Insufficiency, Chronic with a site in Spain that are under way reach primary completion within a year, 8 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06578078Phase 3Fundación para la Investigación del Hospital Clínico de ValenciaA Clinical Trial to Define the Best Strategy for the Management of Heart Failure in Elderly Patients | 2026-12-30 |
| NCT05196035Phase 3BayerA Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria | 2027-04-10 |
| NCT07107945Phase 3Boehringer IngelheimA Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids) | 2027-04-16 |
| NCT03969329Phase 3AmgenA Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis | 2027-06-30 |
| NCT05374291Phase 3University Medical Center GroningenThe RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD | 2027-07 |
Add all 13 to your calendar (.ics) → With an account.
Among the 188 studies in Renal Insufficiency, Chronic with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To date, no rigorous randomized controlled trials have demonstrated a protective effect of daily moderate walnut consumption on kidney function or chronic kidney disease (CKD) progression in individuals with CKD.
Objective: To determine the effect of walnut supplementation (30 g/day of raw walnuts) within a Mediterranean diet (MedDiet) based dietary counseling program, compared with the same MedDiet counseling program without walnut supplementation, on kidney function, CKD progression and regression, and classical and emerging cardiovascular risk markers in individuals with CKD. Secondary objectives focus on assessing whether regular walnut consumption as a healthy snack has a positive impact on inflammation, oxidative stress, endothelial dysfunction, and intestinal dysbiosis, conditions intrinsically linked to CKD that play a pathophysiological role in promoting/exacerbating its progression and the development of comorbidities in this vulnerable group of subjects.
Methodology: A 6-month randomized controlled trial will be conducted in 150 men and women aged 45 to 75 years with stable mild to moderate CKD (stage G3a-b), overweight or obesity, and high cardiometabolic risk. The study will compare the effect of two interventions assessed at 3 and 6 months on the following outcomes:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Meet at least one of the following conditions:
(i) Systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg, or use of antihypertensive agents (ii) Triglycerides ≥150 mg/dL, LDL cholesterol ≥160 mg/dL, HDL cholesterol ≤40 mg/dL in men or ≤50 mg/dL in women, or use of lipid-modifying medication (iii) Prediabetes or type 2 diabetes according to the American Diabetes Association (ADA) Standards, or use of glucose-lowering medication.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in the intervention group will consume 30 g/day of raw walnuts in addition to receiving a Mediterranean diet (MedDiet)-based dietary counseling program. To ensure and facilitate adherence, participants will receive two educational leaflets: one providing practical guidance on following a MedDiet and another containing MedDiet-compatible recipes incorporating walnuts. They will also receive written guidance on optimizing phosphorus and potassium intake within a Mediterranean dietary pattern, including information on food sources, hidden additives, and cooking techniques that may reduce mineral content. Walnuts will be provided free of charge and distributed at baseline and at each follow-up visit.
Other: Daily Walnut Consumption
Participants in the control group will receive the same MedDiet-based dietary counseling without walnut supplementation.
Participants in the intervention group will consume 30 g/day of raw walnuts for 6 months in addition to receiving a Mediterranean diet (MedDiet)-based dietary counseling program.
Change from baseline in renal function
Renal function will be estimated using the estimated glomerular filtration rate (eGFR) calculated from serum creatinine (eGFRcr), cystatin-C (eGFRcys), or both (eGFRcr-cys), applying the CKD-Epidemiology Collaboration 2021 equation. Serum creatinine and cystatin C concentrations will be obtained from routine biochemical analyses performed as part of the participants' standard clinical care at the hospital.
Time frame: Participants will be followed for 6 months, with renal function assessments conducted at baseline, at the 3-month follow up period, and at the end of the 6-month follow-up period.
Chronic Kidney Disease (CKD) Progression
CKD progression will be assessed using eGFRcr-cys and defined as the first occurrence, during the 6-month intervention period, of any of the following criteria: (i) a decline in eGFRcr-cys of \>2.5 mL/min/1.73 m² from baseline; (ii) a relative decline in eGFRcr-cys of \>10% from baseline; or (iii) progression to a more advanced stage of kidney function impairment, defined as a transition from G3a to G3b or from G3b to G4 or higher.
Time frame: CKD progression will be evaluated at the end of the 6-month follow-up period.
Chronic Kidney Disease (CKD) remission
CKD remission will be assessed using eGFRcr-cys and defined as the first occurrence, during the 6-month intervention period, of any of the following criteria: (i) an increase in eGFRcr-cys of \>2.5 mL/min/1.73 m² from baseline; or (ii) improvement to a less advanced stage of kidney function impairment, defined as a transition from G3b to G3a or from G3a to G2 or lower.
Time frame: CKD remission will be evaluated at the end of the 6-month follow-up period.
Change from baseline in urinary albumin-to-creatinine ratio (UACR)
The urinary albumin-to-creatinine ratio (UACR, mg/g) will be calculated from urinary albumin and creatinine concentrations measured in first-morning urine samples collected during routine clinical follow-up at the hospital by qualified healthcare personnel, following standard collection and laboratory procedures.
Time frame: Participants will be followed for 6 months. Measurements will be done at baseline, at the 3-month follow-up period, and at the end of the 6-month follow-up period
Change from baseline in mineral and bone metabolism markers
Mineral and bone metabolism markers, including potassium, phosphorus, calcium, vitamin D, and parathyroid hormone, will be measured using standardized methods as part of routine fasting blood biochemical analyses.
Time frame: Participants will be followed for 6 months. Measurements will be done at baseline, at the 3-month follow-up period, and at the end of the 6-month follow-up period.
Change from baseline in body weight
Body weight will be measured in kilograms (kg) by trained personnel using a calibrated scale, with participants lightly dressed and barefoot.
Time frame: Participants will be followed for 6 months. Measurements will be done at baseline, at the 3-month follow-up period, and at the end of the 6-month follow-up period.
Change from baseline in waist circumference
Waist circumference will be measured in centimeters (cm) by trained personnel at the midpoint between the lowest rib and the iliac crest, using a non-stretchable anthropometric tape.
Time frame: Participants will be followed for 6 months. Measurements will be done at baseline, at the 3-month follow-up period, and at the end of the 6-month follow-up period.
Change from baseline in Body Mass Index (BMI)
Body weight and height will be used to calculate body mass index (BMI), expressed in kg/m².
Time frame: Participants will be followed for 6 months. Measurements will be done at baseline, at the 3-month follow-up period, and at the end of the 6-month follow-up period.
Change from baseline in body composition
Body composition will be assessed using dual-energy X-ray absorptiometry (DXA), including measures of general adiposity, such as total fat mass in grams and total body fat percentage, and regional adiposity, including trunk, leg, android, and gynoid fat mass in grams.
Time frame: Participants will be followed for 6 months. Measurements will be done at baseline, and at the end of the 6-month follow-up period.
Change from baseline in bone mineral density
Bone mineral density will be assessed using dual-energy X-ray absorptiometry (DXA).
Time frame: Participants will be followed for 6 months. Measurements will be done at baseline, and at the end of the 6-month follow-up period.
Change from baseline in diet quality
Diet will be assessed using a validated 143-item semiquantitative food frequency questionnaire and the 14-item Mediterranean Diet Adherence Screener (MEDAS). The Mediterranean Diet Adherence Screener score ranges from 0 to 14, with higher scores indicating greater adherence to the Mediterranean diet.
Time frame: Participants will be followed for 6 months. Measurements will be done at baseline, at the 3-month follow-up period, and at the end of the 6-month follow-up period.
Change from baseline in physical activity
Physical activity will be assessed using the validated Registre Gironí del Cor (REGICOR) questionnaire, which estimates energy expenditure in total leisure-time physical activity and according to intensity, including light, moderate, and vigorous activity. Physical activity will be expressed in metabolic equivalents (METs), with higher values indicating greater levels of physical activity.
Time frame: Participants will be followed for 6 months. Measurements will be done at baseline, and at the end of the 6-month follow-up period.
Change from baseline in medication use affecting glomerular hemodynamics
Medication use will be assessed by administering a general questionnaire by trained personnel, and from the patient's medical history.
Time frame: Participants will be followed for 6 months. Measurements will be done at baseline, at the 3-month follow up period, and at the end of the 6-month follow-up period.
Change from baseline in severity of depressive symptoms
Severity of depressive symptoms will be evaluated using the self-administered Patient Health Questionnaire-9 (PHQ-9). The PHQ-9 is a validated and widely used tool, composed of nine items scored from 0 to 3 (max. 27), which correspond to the DSM-IV criteria and allow depression to be classified as minimal, mild, moderate, moderately severe and severe. Higher scores indicate greater severity of depressive symptoms.
Time frame: Participants will be followed for 6 months. Measurements will be done at baseline, and at the end of the 6-month follow-up period.
Change from baseline in severity of anxiety symptoms
Severity of anxiety symptoms will be evaluated using the self-administered Generalized Anxiety Disorder-7 (GAD-7) questionnaire, a brief seven-item scale in which each item is scored from 0 to 3, with a total score from 0 to 21. Higher scores indicate greater severity of anxiety symptoms.
Time frame: Participants will be followed for 6 months. Measurements will be done at baseline, and at the end of the 6-month follow-up period.
Change from baseline in quality of life
Quality of life will be assessed using the Kidney Disease Quality of Life-36 (KDQOL-36) questionnaire, a validated instrument for individuals with mild-to-moderate chronic kidney disease that includes the 12-Item Short Form Health Survey (SF-12) and kidney disease-specific subscales: Symptoms and Problems, Effects of Kidney Disease, and Burden of Kidney Disease. Scores for each domain range from 0 to 100, with higher scores indicating better health-related quality of life and a lower perceived burden of disease.
Time frame: Participants will be followed for 6 months. Measurements will be done at baseline, and at the end of the 6-month follow-up period.
Change from baseline in fasting glucose
Fasting blood glucose will be measured in mg/dL using standardized methods as part of routine fasting blood biochemical analyses.
Time frame: Participants will be followed for 6 months. Measurements will be done at baseline, at the 3-month follow up period, and at the end of the 6-month follow-up period.
Change from baseline in glycated hemoglobin
Glycated Hemoglobin (%) will be measured using standardized methods as part of routine fasting blood biochemical analyses.
Time frame: Participants will be followed for 6 months. Measurements will be done at baseline, at the 3-month follow-up period, and at the end of the 6-month follow-up period.
Changes from baseline in lipid profile
Total cholesterol, LDL-cholesterol, HDL-cholesterol, non-HDL-C, triglycerides and lipoprotein A will be measured in mg/dL, using standardized methods as part of routine fasting blood biochemical analyses.
Time frame: Participants will be followed for 6 months. Measurements will be done at baseline, at the 3-month follow-up period, and at the end of the 6-month follow-up period.
Change from baseline in blood pressure
Systolic and diastolic blood pressure (mmHg) will be determined after 5 minutes of rest by trained personnel, in triplicate using a semi-automatic oscillometric blood pressure monitor. The participant will be seated and will use their non-dominant arm.
Time frame: Participants will be followed for 6 months. Measurements will be done at baseline, at the 3-month follow-up period, and at the end of the 6-month follow-up period.
Change from baseline in iron status markers
Iron status markers (serum iron, ferritin, transferrin, and transferrin saturation), will be measured using standardized methods as part of routine fasting blood biochemical analyses.
Time frame: Participants will be followed for 6 months. Measurements will be done at baseline, at the 3-month follow up period, and at the end of the 6-month follow-up period.
Change from baseline in hepatic function markers
Hepatic function markers (AST, ALT, and GGT) will be measured using standardized methods as part of routine fasting blood biochemical analyses.
Time frame: Participants will be followed for 6 months. Measurements will be done at baseline, at the 3-month follow up period, and at the end of the 6-month follow-up period.
Change from baseline in lipoprotein profile (particle composition and size)
Lipoprotein profile, including VLDL, LDL, and HDL subfractions composition and size, will be analyzed in fasting blood samples stored at -80 °C in the Biobank using the Advanced Lipoprotein Profile Liposcale® test, based on proton nuclear magnetic resonance (H-NMR) spectroscopy.
Time frame: Participants will be followed for 6 months. Measurements will be done at baseline, and at the end of the 6-month follow-up period.
Change from baseline in oxidative markers
Oxidative stress markers, including oxidized low-density lipoprotein (LDL-ox) and malondialdehyde (MDA), will be measured in fasting blood samples stored at -80 °C in the Biobank using commercially available enzyme-linked immunosorbent assays (ELISAs).
Time frame: Participants will be followed for 6 months. Measurements will be done at baseline, and at the end of the 6-month follow-up period.
Change from baseline in inflammatory markers
Inflammatory markers, including interleukin-1 beta (IL-1β), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-10 (IL-10), tumor necrosis factor-alpha (TNF-α), adiponectin, and leptin, will be measured in fasting blood samples stored at -80 °C in the Biobank using a multiplex immunoassay.
Time frame: Participants will be followed for 6 months. Measurements will be done at baseline, and at the end of the 6-month follow-up period.
Change from baseline in endothelial function markers
Endothelial function markers (VCAM-1, ICAM-1, E-selectin, and P-selectin) will be assessed in fasting blood samples stored at -80 °C in the Biobank using a multiplex immunoassay.
Time frame: Participants will be followed for 6 months. Measurements will be done at baseline, and at the end of the 6-month follow-up period.
Change from baseline in gut microbiota composition
Gut microbiota composition will be assessed by shotgun metagenomic sequencing following DNA extraction, with subsequent taxonomic characterization of microbial diversity and functional potential using established bioinformatics pipelines. Participants will receive instructions and a collection kit for stool sample collection. Samples will be submitted frozen, processed, aliquoted, and stored at -80 °C in the Biobank until analysis.
Time frame: Participants will be followed for 6 months. Measurements will be done at baseline, and at the end of the 6-month follow-up period.
Plan to share: Undecided
No publications or documents are linked to this record.
Started Aug 2026 (actual). Primary completion is estimated for Feb 2028, 18 months after the start.
Of 580 non-industry interventional studies with no phase under Renal Insufficiency, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 45. This study's planned 18 months is below that.
Counting every sponsor, half of 620 studies reached it within 23 months; a quarter within 10 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Renal Insufficiency, Chronic →
Institut Investigacio Sanitaria Pere Virgili